Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651226 | 0.87 | THRB (0.54) | MAPTTP53TBXA2RDRD2LMNA | |
| SCHEMBL2652219 | 0.78 | GCGR (0.50) | TBXA2RDRD2PPARGGCGR | |
| SCHEMBL9251467 | 0.76 | JAK2 (0.49) | MAPTTP53TBXA2RDRD2LMNA | |
| SCHEMBL2650795 | 0.76 | PPARG (0.47) | MAPTTP53PPARGGCGRHDAC1 | |
| SCHEMBL2651771 | 0.76 | GCGR (0.44) | TBXA2RDRD2PPARGGCGRTDP1 | |
| Bromide SCHEMBL9412620 | 0.73 | HDAC6 (0.47) | MAPTHDAC1HDAC8 | |
| SCHEMBL2652185 | 0.73 | GCGR (0.60) | GCGR | |
| SCHEMBL2653126 | 0.72 | HDAC1 (0.61) | MAPTTP53HDAC1HDAC8 | |
| SCHEMBL2655339 | 0.72 | HDAC1 (0.46) | TP53TBXA2RDRD2PPARGGCGR | |
| SCHEMBL2654051 | 0.69 | PPARG (0.55) | MAPTTBXA2RPPARGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | MAPT 4512/4885TP53 4642/4885TBXA2R 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.